Laura J Havrilesky

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA Duke Cancer Institute, Durham, NC, 27710, USA Electronic address
    Gynecol Oncol 131:140-6. 2013
  2. doi request reprint Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center Duke Cancer Institute, Durham, NC 27710, USA
    Gynecol Oncol 125:631-4. 2012
  3. ncbi request reprint Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Gynecol Oncol 88:51-7. 2003
  4. ncbi request reprint Outcomes in surgical stage I uterine papillary serous carcinoma
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 105:677-82. 2007
  5. ncbi request reprint Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710, USA
    Am J Obstet Gynecol 203:160.e1-7. 2010
  6. ncbi request reprint Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Cente, Durham, North Carolina 27710, USA
    Gynecol Oncol 114:279-83. 2009
  7. doi request reprint Cost-effectiveness analysis of annual screening strategies for endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Am J Obstet Gynecol 200:640.e1-8. 2009
  8. pmc Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham NC 27710, USA
    Gynecol Oncol 113:216-20. 2009
  9. ncbi request reprint Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 110:374-82. 2008
  10. pmc Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 26:4144-50. 2008

Detail Information

Publications76

  1. doi request reprint How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA Duke Cancer Institute, Durham, NC, 27710, USA Electronic address
    Gynecol Oncol 131:140-6. 2013
    ..This study aimed to assess the value of a randomized controlled trial (RCT) of lymph node dissection (LND) at the time of hysterectomy for high-risk subsets of women with endometrial cancer...
  2. doi request reprint Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center Duke Cancer Institute, Durham, NC 27710, USA
    Gynecol Oncol 125:631-4. 2012
    ..To determine the potential economic impact of a paclitaxel drug shortage in patients with newly diagnosed, untreated ovarian cancer...
  3. ncbi request reprint Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Gynecol Oncol 88:51-7. 2003
    ..Combination paclitaxel and carboplatin is a well-established first-line regimen for ovarian cancer. The purpose of this study was to evaluate weekly low-dose paclitaxel and carboplatin in recurrent ovarian or peritoneal cancer...
  4. ncbi request reprint Outcomes in surgical stage I uterine papillary serous carcinoma
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 105:677-82. 2007
    ..The optimal management of patients with stage I uterine papillary serous carcinoma (UPSC) is unclear. We sought to determine whether outcomes of women with surgical stage I UPSC differ with and without adjuvant therapy...
  5. ncbi request reprint Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710, USA
    Am J Obstet Gynecol 203:160.e1-7. 2010
    ..We sought to estimate mean costs of chemotherapy treatment for recurrent ovarian cancer with or without use of a chemoresponse assay...
  6. ncbi request reprint Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Cente, Durham, North Carolina 27710, USA
    Gynecol Oncol 114:279-83. 2009
    ..To determine factors related to recurrence and survival in women with stage IIIA endometrial cancer; to examine outcomes of women with IIIA1 disease...
  7. doi request reprint Cost-effectiveness analysis of annual screening strategies for endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Am J Obstet Gynecol 200:640.e1-8. 2009
    ..The objective of the study was to determine the cost-effectiveness of annual screening tests for endometrial cancer...
  8. pmc Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham NC 27710, USA
    Gynecol Oncol 113:216-20. 2009
    ..1) To define a set of health state descriptions related to screening, diagnosis, prognosis, and toxicities relevant to ovarian cancer; (2) To derive a set of quality of life-related utilities to be used for cost-effectiveness analyses...
  9. ncbi request reprint Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 110:374-82. 2008
    ....
  10. pmc Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 26:4144-50. 2008
    ..To determine the cost effectiveness of intraperitoneal versus intravenous regimens for adjuvant treatment of optimally resected stage III ovarian cancer...
  11. ncbi request reprint Cost effectiveness of a test to detect metastases for endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 112:526-30. 2009
    ..To estimate the potential cost-effectiveness of a hypothetical test to screen for lymph node metastases in women with newly diagnosed, apparent early stage endometrial cancer...
  12. ncbi request reprint The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 104:401-5. 2007
    ..We sought to determine whether recurrence and survival of patients with stage IIIA endometrial cancer differ with surgical pathologic findings (positive peritoneal cytology versus positive adnexae or serosa) and adjuvant treatment...
  13. doi request reprint Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 117:545-53. 2011
    ..The objective of the current study was to estimate the impact of a 2-phenotype paradigm of epithelial ovarian cancer on the mortality reduction achievable using available screening technologies...
  14. doi request reprint Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 118:386-91. 2012
    ..The objective of the current study was to construct a cost-utility model to compare these 2 regimens with the incorporation of prospectively collected quality-of-life (QoL) data...
  15. ncbi request reprint FDG-PET for management of cervical and ovarian cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 97:183-91. 2005
    ..To assess the diagnostic performance of Positron Emission Tomography using fluorodeoxyglucose (FDG-PET) in comparison to conventional imaging modalities in the assessment of patients with cervical and ovarian cancer...
  16. ncbi request reprint Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 93:429-34. 2004
    ..We wished to evaluate survival and adverse outcomes of patients with stage IB2 cervical cancer treated primarily with radical hysterectomy and lymphadenectomy...
  17. ncbi request reprint The role of PET scanning in the detection of recurrent cervical cancer
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 90:186-90. 2003
    ..Little is known about the efficacy of PET for detecting recurrent disease. We evaluated the potential role of FDG PET in the context of suspected recurrent cervical cancer...
  18. ncbi request reprint Resection of lymph node metastases influences survival in stage IIIC endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 99:689-95. 2005
    ..Our objective was to compare survival of patients who underwent resection of grossly positive lymph nodes (LN) to those with microscopically positive LN...
  19. ncbi request reprint The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 107:285-91. 2007
    ..We sought to determine the outcome of patients with advanced stage endometrial cancer treated with postoperative chemotherapy+/-radiation to determine whether there was an advantage to combining treatment modalities...
  20. doi request reprint Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer
    Jason C Barnett
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC, USA
    Am J Obstet Gynecol 205:143.e1-6. 2011
    ..The objective of the study was to compare adverse event rates between laparoscopic vs open surgery for endometrial cancer...
  21. ncbi request reprint Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study
    Jennifer M Rubatt
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 112:469-74. 2009
    ..The aims of this study were to examine prognostic significance of microvessel density (MVD) in previously-untreated, advanced epithelial ovarian cancer (EOC) and explore associations between MVD and factors that affect angiogenesis...
  22. ncbi request reprint An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
    Amanda Nickles Fader
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Cleveland Clinic, Cleveland, OH, USA
    Gynecol Oncol 115:244-8. 2009
    ..However, clinicopathologic risk factors for recurrence are not well understood. This study was undertaken to define the prognostic factors for recurrence and survival in patients with early-stage UPSC...
  23. doi request reprint A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 118:3283-93. 2012
    ..The aim of this randomized clinical trial was to evaluate the efficacy and safety of combination (cDC) and sequential (sDC) weekly docetaxel and carboplatin in women with recurrent platinum-sensitive epithelial ovarian cancer (EOC)...
  24. ncbi request reprint Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer
    Janiel M Cragun
    Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    J Clin Oncol 23:3668-75. 2005
    ..Our goal was to assess effects of the extent of selective lymphadenectomy on outcomes in women with apparent stage I endometrial cancer at laparotomy...
  25. ncbi request reprint Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Box 3079, Duke University Medical Center, Durham, NC 27710, USA
    Int J Clin Oncol 12:31-6. 2007
    ..The purpose of this study was to evaluate the toxicity profile of weekly low-dose paclitaxel and carboplatin in patients with gynecologic malignancies...
  26. ncbi request reprint Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 81, Cleveland, Ohio 44195, USA
    Gynecol Oncol 112:558-62. 2009
    ..To determine recurrence patterns and survival outcomes of stage II uterine papillary serous carcinoma (UPSC) patients treated by various modalities with an emphasis on carboplatin/paclitaxel-based chemotherapy (CT)+/-radiotherapy (RT)...
  27. ncbi request reprint Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients
    Chelsea Zhang
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 133:211-5. 2014
    ..The aim of this study is to determine whether a minimally invasive approach to hysterectomy is associated with an increased rate of lymph vascular space invasion (LVSI) and/or malignant pelvic peritoneal cytology in endometrial cancer...
  28. ncbi request reprint Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group s
    Elizabeth L Jewell
    Duke University Medical Center 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 115:424-9. 2009
    ....
  29. ncbi request reprint Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis
    Elizabeth L Jewell
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Gynecol Oncol 107:532-40. 2007
    ..To estimate the relative cost-effectiveness of treatments for patients with FIGO stage IB2 cervical cancer and no evidence of metastasis as determined by combination of positron emission tomography/computed tomography (PET/CT)...
  30. doi request reprint Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer
    Jason C Barnett
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, San Antonio Military Medical Center, Fort Sam Houston, Texas
    Cancer 119:3653-61. 2013
    ....
  31. doi request reprint Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix
    Neil T Phippen
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, San Antonio Military Medical Center, Fort Sam Houston, TX 78234, USA
    Gynecol Oncol 127:267-72. 2012
    ..We evaluate the cost effectiveness (CE) of these treatment regimens...
  32. doi request reprint The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer
    Junzo P Chino
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
    Int J Radiat Oncol Biol Phys 82:1872-9. 2012
    ..We explored the impact of specific RT modalities (whole pelvic RT [WPRT], vaginal brachytherapy [VB]) and LND status on survival...
  33. ncbi request reprint A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer
    Angeles Alvarez Secord
    Gynecologic Oncology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 114:442-7. 2009
    ....
  34. ncbi request reprint Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    Box 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 101:390-7. 2006
    ..This study examined MASPIN expression in human ovarian cancer, and explored the association between MASPIN and prognosis in patients with advanced stage disease treated with first-line cisplatin, carboplatin and/or paclitaxel...
  35. ncbi request reprint Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 107:211-8. 2007
    ..We wished to compare the cost-effectiveness of three chemotherapy regimens for treatment of recurrent platinum-sensitive ovarian cancer...
  36. doi request reprint Cost of care using prophylactic negative pressure wound vacuum on closed laparotomy incisions
    Lauren S Lewis
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 132:684-9. 2014
    ....
  37. pmc A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer
    Angeles Alvarez Secord
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
    Clin Cancer Res 18:5489-98. 2012
    ..We conducted a phase I study of dasatinib, an oral SRC-family tyrosine kinase inhibitor, in combination with paclitaxel and carboplatin in the treatment of advanced and recurrent epithelial ovarian cancer...
  38. doi request reprint Cost analysis of abdominal, laparoscopic, and robotic-assisted myomectomies
    Millie A Behera
    Divisions of Reproductive Endocrinology and Fertility, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA
    J Minim Invasive Gynecol 19:52-7. 2012
    ..To perform a cost-minimization analysis of abdominal, traditional laparoscopic and robotic-assisted myomectomy...
  39. doi request reprint Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, Ohio, USA
    Cancer 115:2119-27. 2009
    ..A study was undertaken to determine recurrence patterns and survival outcomes of stage I uterine papillary serous carcinoma (UPSC) patients...
  40. doi request reprint Cost-minimization analysis of robotic-assisted, laparoscopic, and abdominal sacrocolpopexy
    John P Judd
    Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Minim Invasive Gynecol 17:493-9. 2010
    ..To perform a cost-minimization analysis comparing robotic-assisted, laparoscopic, and abdominal sacrocolpopexy...
  41. doi request reprint Analgesic and antiemetic needs following minimally invasive vs open staging for endometrial cancer
    Nicole D Fleming
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Am J Obstet Gynecol 204:65.e1-6. 2011
    ..We sought to assess perioperative outcomes of minimally invasive vs open endometrial cancer staging procedures...
  42. doi request reprint Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis
    Rachel Peragallo Urrutia
    Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina 27599 7570, USA
    Obstet Gynecol 122:380-9. 2013
    ..To estimate the risk of venous thromboembolism, stroke, or myocardial infarction (MI) associated with the use of oral contraceptive pills (OCPs) and to describe how these risks vary by dose or formulation...
  43. doi request reprint Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer
    Micael Lopez-Acevedo
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 130:156-61. 2013
    ....
  44. doi request reprint The impact of postoperative nausea and vomiting prophylaxis with dexamethasone on postoperative wound complications in patients undergoing laparotomy for endometrial cancer
    Corey S Bolac
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Anesth Analg 116:1041-7. 2013
    ..We performed this retrospective study to determine whether intraoperative dexamethasone for PONV prevention increases the risk or severity of postoperative wound complications...
  45. doi request reprint Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy?
    William J Lowery
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 126:12-5. 2012
    ..We sought to evaluate the effect of systematic lymphadenectomy (LND) on endometrial cancer-specific survival in an elderly population...
  46. doi request reprint Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma
    Patricia A Convery
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 123:65-70. 2011
    ..To validate the Mayo algorithm to intraoperatively identify women with endometrial cancer in whom lymphadenectomy may be safely omitted...
  47. ncbi request reprint Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer
    Deanna Teoh
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 122:467-72. 2011
    ..To evaluate the costs and effectiveness of thromboprophylaxis strategies following laparotomy for ovarian cancer...
  48. ncbi request reprint Cost comparison among robotic, laparoscopic, and open hysterectomy for endometrial cancer
    Jason C Barnett
    Divisions of Gynecologic Oncology and Urogynecology, Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina 27710, USA
    Obstet Gynecol 116:685-93. 2010
    ..To use decision modeling to compare the costs associated with robotic, laparoscopic, and open hysterectomy for the treatment of endometrial cancer...
  49. doi request reprint Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Duke Cancer Institute, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Gynecol Cancer 23:846-52. 2013
    ....
  50. doi request reprint Preference-based utility scores for adverse events associated with the treatment of gynecologic cancers
    Elizabeth L Jewell
    Division of Gynecology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Gynecol Cancer 23:1158-66. 2013
    ....
  51. doi request reprint A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer
    Angeles Alvarez Secord
    Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 128:65-70. 2013
    ..To determine if there is an advantage to combination chemotherapy and radiation for optimally resected stage IIIC endometrial cancer (EC)...
  52. doi request reprint Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists
    Angeles Alvarez Secord
    Duke University Medical Center, Durham, NC 27710, USA
    Int J Gynecol Cancer 19:447-54. 2009
    ....
  53. ncbi request reprint Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    DUMC 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 106:221-32. 2007
    ....
  54. doi request reprint Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 111:179-87. 2008
    ..We wished to estimate the clinical impact and cost-effectiveness of potential screening strategies for ovarian cancer using population-specific data...
  55. ncbi request reprint The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma
    Nikki L Neubauer
    Department of Obstetrics and Gynecology, Division of Gynecology Oncology Duke University Medical Center Durham, NC 27710, USA
    Gynecol Oncol 112:511-6. 2009
    ..We sought to assess the accuracy of a preoperative grade 1 designation and role of lymphadenectomy in women with preoperative grade 1 endometrial cancer...
  56. doi request reprint The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study
    Angeles Alvarez Secord
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 123:314-9. 2011
    ..To elucidate the regulation of MASPIN expression in epithelial ovarian cancer (EOC) and associations with p53 status and MASPIN promoter methylation...
  57. pmc Robotic-assisted laparoscopic gynecologic procedures in a fellowship training program
    Paula S Lee
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    JSLS 13:467-72. 2009
    ..Our goal was to perform an early evaluation of the feasibility of training fellows in robotic-assisted gynecologic procedures at the outset of our incorporation of this technology into clinical practice...
  58. doi request reprint Utility scores and treatment preferences for clinical early-stage cervical cancer
    Elizabeth L Jewell
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
    Value Health 14:582-6. 2011
    ..To determine utility scores for health states relevant to the treatment of early-stage, high-risk cervical cancer...
  59. ncbi request reprint Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?
    Neil T Phippen
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, San Antonio Military Medical Center, Fort Sam Houston, TX 78234, USA
    Gynecol Oncol 130:317-22. 2013
    ....
  60. doi request reprint Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer
    Robin A Laskey
    Department of Obstetrics and Gynecology, Duke University Medical Center, USA
    Gynecol Oncol 125:625-30. 2012
    ..To identify factors that increase the risk of neutropenic events in women with advanced ovarian carcinoma receiving initial chemotherapy...
  61. doi request reprint Palliative and hospice care in gynecologic cancer: a review
    Micael Lopez-Acevedo
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
    Gynecol Oncol 131:215-21. 2013
    ..This review of the literature explores the current state of palliative care in the treatment of gynecologic cancers and its implications for the quality and cost of this treatment. ..
  62. doi request reprint Projecting the need for gynecologic oncologists for the next 40 years
    Amy H Wallace
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Obstet Gynecol 116:1366-72. 2010
    ..To estimate the ratio of gynecologic cancer cases to practicing gynecologic oncologists in the United States over the next 40 years...
  63. doi request reprint Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence
    Jennifer M Wu
    Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina 27710, USA
    J Urol 181:2181-6. 2009
    ..We assessed the cost-effectiveness of botulinum toxin A injection compared to anticholinergic medications for the treatment of idiopathic urge incontinence...
  64. ncbi request reprint Predictors of clinical outcomes in the laparoscopic management of adnexal masses
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA
    Obstet Gynecol 102:243-51. 2003
    ..Laparoscopy has become an accepted approach in the management of adnexal masses. We evaluated clinical outcomes of laparoscopic management of adnexal masses thought to be benign preoperatively...
  65. ncbi request reprint Clinical and pathologic correlates in surgical stage II endometrial carcinoma
    David E Cohn
    Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, Ohio, USA
    Obstet Gynecol 109:1062-7. 2007
    ..To identify the surgical, pathologic, and therapeutic factors that influence outcome in patients with surgical stage II endometrial adenocarcinoma...
  66. ncbi request reprint High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease
    Ted M Roth
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 91:258-60. 2003
    ..Intraoperative radiation therapy (IORT) has demonstrated encouraging results. Patients have traditionally been excluded from IORT if they had distant metastases...
  67. ncbi request reprint Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Obstet Gynecol 122:139-47. 2013
    ..To estimate the overall reduction in ovarian cancer risk associated with the use of oral contraceptive pills (OCPs) and whether reduction in risk is affected by specifics of OCP use, such as formulation or duration of use...
  68. pmc A branching process model of ovarian cancer
    Kaveh Danesh
    Department of Mathematics, Duke University, Box 90230, Durham, NC 27708 0320, USA
    J Theor Biol 314:10-5. 2012
    ..9 years, indicating that one would have to screen at least every other year to be effective. The model can be used to inform future efforts in designing improved screening and treatment strategies...
  69. ncbi request reprint A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma
    Ellen L Jones
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 98:277-82. 2003
    ..The authors evaluated response and toxicity in patients with locally advanced cervical carcinoma (LACC) who were treated with concurrent weekly CDDP, HT, and RT (whole pelvis [n=7] and whole pelvis and paraaortic nodes [n=5])...
  70. ncbi request reprint Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity
    John T Soper
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 97:596-601. 2005
    ..To compare flap-specific complications of rectus abdominis myocutaneous (RAM) and myoperitoneal (RAMP) flap neovagina reconstructions performed concurrently with radical pelvic procedures...
  71. doi request reprint Preoperative screening strategies for bacterial vaginosis prior to elective hysterectomy: a cost comparison study
    Kara A McElligott
    Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC, USA
    Am J Obstet Gynecol 205:500.e1-7. 2011
    ..For comparison purposes, a fourth strategy is examined: (4) no surgical site infection prophylaxis or bacterial vaginosis treatment...
  72. ncbi request reprint Medical and surgical treatment of placenta percreta to optimize bladder preservation
    Paula S Lee
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and Division of Maternal and Fetal Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Obstet Gynecol 112:421-4. 2008
    ..Placenta percreta is associated with significant morbidity and mortality. Interventions are dictated by hemodynamic stability, desire to retain future fertility, and efforts to reduce surgical morbidity at time of delivery...
  73. ncbi request reprint A review of cost-effectiveness studies in ovarian cancer
    Gregory P Sfakianos
    Duke University Medical Center, Division of Gynecologic Oncology, DUMC 3079, Durham, NC 27710, USA
    Cancer Control 18:59-64. 2011
    ..Cost-effectiveness models take into account costs, effects, and quality of life and provide clinicians with useful tools to aid in making these difficult decisions...
  74. pmc Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer
    Zhen Zhang
    Center for Biomarker Discovery, Department of Pathology, Johns Hopkins Medical Institutions, CRB II 3M04, 1550 Orleans Street, Baltimore, MD 21231, USA
    Gynecol Oncol 107:526-31. 2007
    ..In this paper, an ANN model was evaluated for its performance in detecting early stage epithelial ovarian cancer using multiple serum markers...
  75. ncbi request reprint Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions
    Steven J Skates
    Massachusetts General Hospital, 50 Stanford St, Suite 560, Boston, MA 02114, USA
    J Clin Oncol 22:4059-66. 2004
    ..For direct comparisons between marker panels, all sensitivity results correspond to a 98% fixed first-line specificity (referral rate 2%)...
  76. ncbi request reprint Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology
    Christopher V Lutman
    Riverside Gynecologic Oncology, Columbus, OH 43214, USA
    Gynecol Oncol 102:92-7. 2006
    ..To determine whether pelvic lymph node count is associated with patterns of recurrence or survival in patients with FIGO stage I and II endometrial cancer...